Sign Up
Ready to replace complexity with clarity?
Answer your real world compliance questions (limited time) and save thousands in legal fees and avoided fines.
Automate Compliance TodayUS states A to Z: marijuana, THCA, delta-8, delta-9, delta-10, HHC
State-by-state mapMost read countries: marijuana, CBD and hemp status
All countries on the globeSubstances: status in every state for each one
Compare all substancesFederal hemp redefinition: P.L. 119-103, div. B, sec. 2019
Nov 12, 2026
Applies only to cannabinoids the plant cannot naturally produce.
Dec 11, 2026
The total-THC test, the 0.4 mg per container cap and the exclusion of converted cannabinoids start.
Latest regulatory actions, updated daily
All regulatory actionsHeadlines and the first four sentences are free. Full write-ups, impact reasoning and the archive are for members.
Member · $99/mo
Every rule change, the day it is made.
The price will rise. Join now and $99 a month stays your rate for life.
Become a memberOr read free: every action opens 30 days after it is published. Sign in with email
By topic
Licensing and permitsPackaging and labelingLab testing and QARetail complianceAdvertising and marketingBanking and paymentsTaxesShipping and logisticsTravel and transportLitigationSOPsFor your role
Regulators and agenciesBrands and operatorsRetailers and smoke shopsCultivatorsProcessorsLawyers and complianceInvestorsConsumers and travelersThe Regulator Brief · newsletter
Every rule change that matters, every Monday.
Free: the Monday brief, and every action 30 days after it is published.
Members: the paid weekly, daily alerts and every write-up.
Read by regulators, operators, lawyers and founders.
Cannabis lawyers
Licensed by state. Listings are not endorsements.
By state
Software and services
Compared by fit, never ranked.
Categories
For companies and firms
Be the listing operators and regulators find.
Software and services
Verified, $49/mo: domain-verified badge, your website link, a quote.
Featured, from $399/mo: labeled Featured in your category, monthly release notes.
Lawyers and firms
Claimed, $75/yr: Claimed badge and your firm's website link.
Featured, $199/mo: labeled Featured on your profile.
Claim your companyClaim a lawyer listingPlacements, flat monthly fee
State and country page sponsorshipsExclusive slot on a legality page and its postsRegulator Brief sponsorshipPresenting sponsor or mid-issue banner, free editionMember brief sponsor slotThe paid weekly, read by members onlyFeatured directory placementLabeled Featured in a software categoryCategory sponsorshipOwn one directory category across the sitePaid guest postsLabeled Paid guest post, sponsored linksWrite and partner
Pitch a paid guest postRead guest postsBecome an affiliateSend a tip or correctionContact the teamWho reads it
Regulators at federal, state and county agencies, plus the operators, lawyers and founders they regulate.
Get the media kitSee open placementsSubstances
US states, map and A to ZCountriesFederal hemp 2026: Nov 12 and Dec 11Compound index, every stateTravelling with cannabis or hempMembers get the daily alert email and every full write-up the morning it is published. Every action is free to read 30 days later.
For your role
All news and analysisGuidesAnalysisFAQsTemplates and SOPsCourt filing recapsNews by state and countrySoftware and services: Verified $49/mo, Featured from $399/mo. Lawyers and firms: Claimed $75/yr, Featured $199/mo. Listings are not endorsements.
Regulatory journalism, not legal advice. How we report

JECFA CBD 2025: Global Brands Still Face an Unresolved Gray Area
The 100th session of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), convened in mid-2025, was widely anticipated by the international cannabis and food sectors. Stakeholders hoped JECFA might finally provide unified, science-based safety benchmarks for cannabidiol (CBD) in foods—a move that could catalyze product innovation, stabilize regulatory outlooks, and expand CBD’s global reach. However, the outcome was less definitive: JECFA’s recent proceedings did not establish clear, harmonized safety thresholds for CBD in food and supplements, leaving the patchwork of country-specific regulations intact for at least the foreseeable future.
Earlier communications from JECFA indicated optimism about developing a reference dose for non-intoxicating CBD in foodstuffs. Yet, the final reports from the 100th JECFA meeting confirmed what many compliance teams feared: ongoing data gaps—especially around chronic use, sensitive populations, and certain delivery forms—meant that the group could not complete a comprehensive safety evaluation for several use-cases. This means the international Codex Alimentarius Commission, which frequently uses JECFA’s scientific advisories to set standards for food safety worldwide, remains without a globally enforceable CBD guideline (FAO/WHO JECFA, 2025).
The lack of JECFA benchmarks has a direct impact on Codex member countries: rather than defaulting to a universal limit for CBD in food and beverages, each nation continues to manage CBD regulation based on their own risk assessments and evolving consumer protection stances. For multinational cannabis or food brands, this means that product formulations, dosage limits, and label claims must remain highly localized.
In the UK, the Food Standards Agency (FSA) continues its case-by-case approach to authorizing CBD products under the Novel Foods regime. Despite dozens of applications, as of Q3 2025, only a select few products have advanced beyond the validation phase, and final market authorizations are rare. The FSA maintains a dynamic public list of CBD products permitted for sale, and compliance teams must cross-reference this list against their inventory and distribution plans (FSA Novel Foods Status).
Across the European Union, the European Food Safety Authority (EFSA) still has not issued a clear positive assessment for CBD novel food dossiers. In its 2024–25 updates, EFSA cited insufficient toxicological data and flagged uncertainties about long-term impacts on the liver and endocrine system. In practice, most EU countries either prohibit CBD in foods outright or allow it only under strict tolerance levels, often pending further advice (EFSA CBD Update).
While not a Codex member bound by international harmonization, the U.S. Food and Drug Administration (FDA) still has not recognized CBD as Generally Recognized as Safe (GRAS) for use in foods or dietary supplements. State-level rules continue to evolve, with some jurisdictions permitting retail CBD edibles and others enforcing bans. Recent state actions, such as the tightening of intoxicating hemp derivative laws, further complicate matters for brands targeting multiple U.S. markets (FDA CBD Regulation). For a related FDA docket, see FDA's 2026 botanical drug request for information.
Jurisdictions in Asia-Pacific, including Japan, Singapore, and China, maintain strict prohibitions on ingestible CBD. Latin American countries, once viewed as liberalizing, have recently issued warnings or recalls on cannabinoid-infused products that exceed local tolerances or lack novel food registrations. Compliance teams should continue to monitor these regulatory climates carefully.
In the absence of Codex or JECFA harmonization, brands must sustain parallel product lines tailored to the unique regulatory, dosage, and labeling requirements of each national market. It is critical to:
While JECFA’s scientific reviews are respected in international trade and at the World Trade Organization (WTO), its latest CBD advisories should be considered horizon-scanning tools rather than actionable standards—at least for the next year. Project and compliance planning should factor in the possibility of further scientific review or revised national stances.
With no single global rulebook, enforcement risks and market disruptions remain very real. Countries may issue recalls, restrict distribution, or challenge imports—even on products compliant with JECFA’s general scientific advice. This risk is especially pronounced for online sales and cross-border supply chains.
The ongoing debate around “intoxicating hemp derivatives” (e.g., delta-8-THC products) has prompted several countries to withdraw or tighten previously liberal CBD/hemp policies. Brands should track how these policy debates intersect with overall CBD tolerance schemes.
Direct communication with country regulators, legal advisors, and industry associations is more vital than ever. National interpretations often shift quickly, and proactive engagement increases the chance of early compliance alerts or input into developing guidance.
JECFA’s centennial meeting confirmed the scientific and regulatory complexity still surrounding CBD in foods and supplements:[
Consequently, businesses should not expect fast-tracked international standardization before further research—potentially years down the line. Instead, organizations should:
While Codex Alimentarius standards have resolved other food safety gaps in the past, the uniquely politicized and scientifically unsettled status of CBD means that a globally harmonized benchmark is unlikely until long-term safety data matures. For now, multinationals must accept fragmented markets and regulatory “gray areas” as the norm.
In summary: JECFA 100’s inability to deliver a global CBD food safety standard in 2025 means the landscape for JECFA CBD 2025 compliance is still fragmented and rapidly evolving. Businesses must lean into country-specific diligence, adaptable product strategies, and ongoing horizon-scanning to remain competitive and compliant.
For real-time analysis and compliance support across global cannabis/CBD regulations, consult CannabisRegulations.ai or connect with our regulatory experts.